Global Cell Therapy Manufacturing Market, by Therapy Type (Allogeneic Cell Therapy, Autologous Cell Therapy), by Technology Type (Somatic Cell Technology, Cell Immortalization, Technology, Viral Vector Technology, Genome Editing, Technology, Cell Plasticity Technology, 3D Technology), by Source (IPSC’s (Induced pluripotent stem cell), Bone Marrow, Umbilical Cord, Adipose Tissue, Neural Stem), by Application (Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,755.4 Million in 2022 and is expected to exhibit a CAGR of 15.2% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Manufacturers of cell therapy product candidates are engaged in receiving regulatory approvals to enhance their cell therapy manufacturing process, which in turn is expected to drive the global cell therapy manufacturing market growth. For instance, in April 2022, Kite, a subsidiary of Gilead Company, announced that the U.S. FDA had approved its CAR T-Cell therapy Yescarta (axicabtagene ciloleucel), for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
Moreover, in March 2022, the U.S. FDA approved Janssen Pharmaceutical Companies’s CAR T Cell Therapy ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of patients with relapsed/refractory multiple myeloma.
Global Cell Therapy Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the cell therapy manufacturing market, owing to the increasing efforts by the key players in the market to develop vaccines for COVID-19 infection. For instance, according to an article published by Frontiers Media S.A., in November 2021, stem cell therapy has shown a positive effect on reducing mortality and morbidity of patients with COVID-19. Moreover, key players operating in market are focusing on development of treatment for COVID-19 using cell therapy, and therefore, are focusing on obtaining regulatory approval for its use. For instance, in April 2022, the U.S. Food and Drug Administration (FDA), announced that it had granted clearance to BioCardia’s (a clinical-stage regenerative medicine company) Investigational New Drug (IND) application to commence a Phase I/II clinical trial of BCDA-04 in adults recovering from Covid-19- linked acute respiratory distress syndrome (ARDS).
Thus, increasing efforts by the key players to develop vaccines and carry research and development activities for COVID-19 infection is expected to drive the market growth over the forecast period.
Global Cell Therapy Manufacturing Market: Key Developments
On July 30, 2021, Astellas Pharma Inc., a Pharmaceutical company announced that it had collaborated with Minovia Therapeutics, Ltd., a clinical-stage international biotechnology company, for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
On August 4, 2022, Thermo Fisher Scientific, an analytical laboratory instrument manufacturing company, announced that the company had expanded cell culture media manufacturing site in Grand Island, New York to meet increasing global demand for cell culture media used in the manufacturing of new vaccines and biologics.
Browse 41 Market Data Tables and 32 Figures spread through 205 Pages and in-depth TOC on “Global Cell Therapy Manufacturing Market”- Forecast to 2030, Global Cell Therapy Manufacturing Market, by Therapy Type (Allogeneic Cell Therapy, Autologous Cell Therapy), by Technology Type (Somatic Cell Technology, Cell Immortalization, Technology, Viral Vector Technology, Genome Editing, Technology, Cell Plasticity Technology, 3D Technology), by Source (IPSC’s (Induced pluripotent stem cell), Bone Marrow, Umbilical Cord, Adipose Tissue, Neural Stem), by Application (Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cell-therapy-manufacturing-market-1728
Moreover, increasing incidence of vitiligo globally, is expected to drive growth of the global cell therapy manufacturing market over the forecast period. For instance, According to National Center for Biotechnology Information, 2021, Vitiligo is an acquired pigmentation disorder of unknown origin and the most frequent cause of depigmentation, causing an estimated prevalence between 0.5 and 2% worldwide, in the year 2020. The stem cells are used for the treatment of various skin diseases such as vitiligo, etc.
Key Takeaways of the Global Cell Therapy Manufacturing Market:
- The global cell therapy manufacturing market is expected to exhibit a CAGR of 15.2% during the forecast period due to the increasing adoption of strategies such as partnerships by the key players. For instance, on May 19, 2021, Thermo Fisher Scientific, an analytical laboratory instrument manufacturing company and the University of California, San Francisco (UCSF) announced that they had formed a strategic partnership to accelerate the development and manufacturing of cell-based therapies.
- Among source, induced pluripotent stem cell (IPSC) segment is estimated to hold a dominant position in the global cell therapy manufacturing market over the forecast period, owing to expansion facility for the production of IPSC’s. For instance, on March 15, 2022, I Peace, Inc., a contract development and manufacturing organization (CDMO) specializing in induced pluripotent stem cells (IPSCs), has expanded its manufacturing facility, tripling the biotech startup’s capacity to produce IPSC cells. The facility is going through a regulatory review and a U.S. Food and Drug Administration (U.S. FDA) registration update. The facility started operating as full time in April 2022
- Among regions, North America is estimated to account for the largest market share in the global cell therapy manufacturing market over the forecast period, owing increasing number of approvals for production by regulatory bodies. For instance, on April 19, 2022, Kite Pharma, a biopharmaceutical company and subsidiary of Gilead Science Company, a biopharmaceutical company, announced that it had received approval for commercial production at the company's new CAR-T cell therapy manufacturing facility in Frederick, Maryland by U.S. Food and Drug Administration (FDA). The site will produce Kite's FDA cleared CAR-T cell therapy for treating blood cancer
- Major players operating in the global cell therapy manufacturing market include WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.
